Accordingly, it is reasonable that elafibranor, through renal PPARα and PPARδ activation, improves CKD through inhibition of renal oxidative stress, inflammation, fibrosis, and apoptosis in HFD-induced obese mice with steatohepatitis in our study. The gene discussed is PPARA; the disease is chronic kidney disease.